NeoTract today presented 5-year results from the pivotal Lift IDE study of its UroLift system, touting rapid reduction of symptoms and sustained effects in treating patients with symptomatic benign prostatic hyperplasia.
The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate.
The 5-year results were presented by Dr. Claus Roehrborn of Dallas’ UT Southwestern Medical Center at the 112th annual American Urological Association meeting in Boston.
Results from the trial indicated that the system and associated procedure was tolerable, and led to a rapid reduction in symptoms while preserving sexual function.
The procedure was also found to have a sustained effect, according to the company, with peak urinary flow rate improving 36% to 44% from the baseline at 5 years. Patients also reported a quality of life improvement of 50% over 5 years, with a retreatment rate of 2-3%.
“The UroLift System has now been proven as a minimally invasive alternative to medication that offers sustained, reliable relief for patients. The procedure itself can be performed efficiently by a trained urologist, with little need for anesthetics or pain medication. It involves no cutting, heating, or removal of tissue, and results are evident immediately. Healing and recovery are swift, with patients experiencing symptom relief and improved quality of life within a matter of days or weeks, and sustained similar results after five years. I truly believe the UroLift System is a game-changer for the field of urology,” Dr. Steven Gange of Salt Lake City, Utah’s Summit Urology Group said in a press release.
“We are excited to share this excellent long-term data with the attendees of AUA. The results continue to demonstrate the potential of the UroLift System to become the standard of care first-line treatment for patients with BPH. NeoTract has set the standard for robust BPH clinical data collection with global multi-site studies and proven durability and it’s an area we will continue to invest in. We are honored to partner with urologists around the world to help men return to normal urinary function and preserve sexual vitality with this safe and effective treatment option,” prez & CEO Dave Amerson said in a press release.